A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1194
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2014 A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. ASO, B2M, ET, GUSB, PLTs, PMF
2014 A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. JAK2
2014 Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort. ET, MF, MPNs
2014 Chronic myeloproliferative diseases. ET, PMF
2014 Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. ET, MGUS, MM, MPNs, PMF
2014 Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. iPSCs
2014 Dkk3 levels in patients with myeloproliferative neoplasms. Dkk-3, ET, MPN, PMF
2014 Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. ET, MF, MPN, PMF
2014 Epidemiology of myeloproliferative neoplasms in the United States. ET, MF, MPNs
10  2014 JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. ET, PLA, TF
11  2014 Masked polycythemia vera (mPV): results of an international study. mPV, mPV
12  2014 Masked polycythemia vera diagnosed according to WHO and BCSH classification. BCSH, BM, Hb, Hct, mPV, WHO
13  2014 Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. ET, MF, MPN
14  2014 Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. ECP, MAP
15  2014 Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN). ET, MF, MPN, OS, SEER, US
16  2013 A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. HC, HDACi, MPN, MTD
17  2013 Aberrant expression of signaling proteins in essential thrombocythemia. ERbeta, ET
18  2013 ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. CAT, ET, TG
19  2013 Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. MPN
20  2013 An unknown cause of aortic valve stenosis: polycythemia vera. Ht
21  2013 Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. FTY720-P, PP2A
22  2013 Are MPNs vascular diseases? ET, MPNs
23  2013 Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. ET, IFN, MF, MPN
24  2013 Characterization of blood donors with high haemoglobin concentration. Hb
25  2013 Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. CI, CML, CMPN, ET
26  2013 Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. ADP, ET, MPN, PRI, VASP, WBC
27  2013 Clinics in diagnostic imaging (146). Polycythaemia vera (PV). ---
28  2013 Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. ET, MF, PMF
29  2013 Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. WBC
30  2013 Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. CMP, HSC, NF-E2
31  2013 Emerging drugs for polycythemia vera. HU
32  2013 Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. ---
33  2013 Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. EPO, RCM, WHO
34  2013 Generation of iPS cells from normal and malignant hematopoietic cells. CML, iPSCs
35  2013 Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-alpha therapy. ET, HHT
36  2013 Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. AS-qPCR, CBC, ET, MPDs, MPV, P-LCR, PDW
37  2013 Inheritance of the chronic myeloproliferative neoplasms. A systematic review. AD, CML, ET, MPNs, PMF
38  2013 JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. ET, JAKs, MPN, PMF
39  2013 JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients. CI, ET, JAK2, MPNs, OR, PMF
40  2013 JAK2 mutation-related disease and thrombosis. ET, MPNs
41  2013 JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. ---
42  2013 Laboratory detection of JAK2V617F in human myeloproliferative neoplasms. ET, PMF
43  2013 Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. ET
44  2013 Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia. ET, MPNs, PMF
45  2013 MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. ET, miRNA
46  2013 MicroRNAs in myeloproliferative neoplasms. ET, miRNA, MPN, PMF
47  2013 Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. CMR, ET, PEG-IFN-alpha-2a
48  2013 Molecular basis of erythrocyte adhesion to endothelial cells in diseases. PS, RAGE, RBC, RVO
49  2013 Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. ET, PM
50  2013 Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. ET, MPN, MPN-SAF, PMF, QOL
51  2013 Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. ET
52  2013 Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. AVWS, CV, ET, MPN
53  2013 Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis. HS
54  2013 Polycythemia vera: current pharmacotherapy and future directions. JAK2
55  2013 Postcoital generalised pruritus as a first symptom of polycythaemia vera. AP, PCP
56  2013 Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. BFU-E, ET, MPN
57  2013 Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. JAK, MPNs, mTOR
58  2013 Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. ELN, ET
59  2013 Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. MPs, PCA, PS
60  2013 Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. ET, JAK, MF
61  2013 Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. CMPD, ET, GDF15
62  2013 Significance of cytogenetic abnormalities in patients with polycythemia vera. ---
63  2013 Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. CI, HR
64  2013 Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. CTR, MF, Ph-neg-CMNs, SE, TL
65  2013 The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm. ARMS, BM, ET, JAK2, PB, PMF, RQ-PCR
66  2013 The evolving treatment paradigm in myelofibrosis. ET, FDA, HSCT, JAK2, MF
67  2013 The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms. EMSA, ET, JAK2, MF, MPN, RQ-PCR, SNP
68  2013 Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. DEX, ERY
69  2013 Treatment and management of myelofibrosis in the era of JAK inhibitors. allo-HSCT, ESAs, ET, JAK, MF
70  2013 Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. CML, CMR, ET, MPNs, PMF, TKIs
71  2013 WHO classification of myeloproliferative neoplasms (MPN): A critical update. ET, MPN, PMF, WHO
72  2013 [Diagnosis and therapy of polycythemia vera in the era of JAK2]. JAK2, MPN
73  2013 [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis]. ET, MPN, PMF, WHO
74  2013 [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin to the end of 2012]. CZEMP, ET, MPDs, PMF
75  2012 A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. ET, OR
76  2012 A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. MPDs
77  2012 Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. aGVHD, CIBMTR, ET, FHCRC, HCT, MA, MF, PFS, TRM
78  2012 Analysis on 71 patients with polycythemia vera. LDH, NSE
79  2012 Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. CI, ELN, HU
80  2012 Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. ET, MF, MPN, PMF
81  2012 Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia. AGEs, AOPPs, ET, NGAL
82  2012 Clinical predictors of outcome in MPN. ET, PMF
83  2012 COLD-PCR and innovative microarray substrates for detecting and genotyping MPL exon 10 W515 substitutions. ET, HRM, MPNs, PMF
84  2012 Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells. ---
85  2012 Critical requirement for Stat5 in a mouse model of polycythemia vera. EPO, ET, MPNs, PMF
86  2012 Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. ET, MPNs, PMF
87  2012 CYP1AI, glutathione S-transferase gene polymorphisms and risk of Polycythemia vera. ORs
88  2012 Decreased neutrophil apoptosis in quiescent ANCA-associated systemic vasculitis. AASV, HBD, RA, SLE, TP
89  2012 Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera. HRM
90  2012 Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. HSCs, LT
91  2012 Dural sinus thrombosis owing to polycythaemia vera in a 12-year-old girl. ---
92  2012 Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera. EPO, JAK2
93  2012 Efficacy of vorinostat in a murine model of polycythemia vera. HEL
94  2012 Electrocardiographic findings in patients with polycythemia vera. ECG
95  2012 Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera. EI
96  2012 Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. CML, MPNs
97  2012 Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: the effect of isovolemic erythrocytapheresis. ECP, MA, PLT, TEG
98  2012 Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. ET, IL
99  2012 Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. ET, MPD
100  2012 Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera. AFIP, Hb, JAK2, PCR